FDA new drug approvals in Q2 2023

被引：0

作者：

Urquhart, Lisa ^{[1
]}

机构：

[1] Evaluate Vantage, London, England

来源：

关键词：

D O I：

10.1038/d41573-023-00117-6

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

引用

页码：614 / 614

页数：1

共 50 条

[1] FDA new drug approvals in Q2 2023
Lisa Urquhart
[J]. Nature Reviews Drug Discovery, 2023, 22 : 614 - 614
[2] FDA new drug approvals in Q2 2021
Lisa Urquhart
[J]. Nature Reviews Drug Discovery, 2021, 20 : 578 - 578
[3] FDA new drug approvals in Q2 2018
Lisa Urquhart
[J]. Nature Reviews Drug Discovery, 2018, 17 : 536 - 537
[4] FDA new drug approvals in Q2 2020
Urquhart, Lisa
[J]. NATURE REVIEWS DRUG DISCOVERY, 2020, 19 (08) : 503 - 503
[5] FDA new drug approvals in Q2 2020
Lisa Urquhart
[J]. Nature Reviews Drug Discovery, 2020, 19 : 503 - 503
[6] FDA new drug approvals in Q2 2019
Lisa Urquhart
[J]. Nature Reviews Drug Discovery, 2019, 18 : 575 - 575
[7] FDA new drug approvals in Q2 2022
Lisa Urquhart
[J]. Nature Reviews Drug Discovery, 2022, 21 : 550 - 550
[8] FDA new drug approvals in Q2 2018
Urquhart, Lisa
[J]. NATURE REVIEWS DRUG DISCOVERY, 2018, 17 (08) : 536 - 537
[9] FDA new drug approvals in Q2 2024
Verdin, Paul
[J]. NATURE REVIEWS DRUG DISCOVERY, 2024, 23 (08) : 573 - 573
[10] MARKET WATCH FDA new drug approvals in Q2 2021
Urquhart, Lisa
[J]. NATURE REVIEWS DRUG DISCOVERY, 2021, 20 (08) : 578 - 578